Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
OMGA Omega Therapeutics
6.350
-0.050-0.78%
Post Mkt Price
6.400
+0.050+0.79%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Receivable Turnover(T)
-- 2.9759 -- 2.8567 -- 1.2815 -- 0.64
Fixed Assets Turnover(T)
-- 0.2415 -- 0.1306 -- 0.0588 -- 0.0406
Total Asset Rate(T)
-- 0.0072 -- 0.0055 -- 0.0023 -- 0.0011
ROIC
-98.01% -47.692% -- -169.333% -- -106.293% -- -81.859%
ROE
-102.91% -52.391% -- -263.353% -- -144.875% -- -100.412%
ROA
-91.86% -44.869% -47.61% -52.900% -59.31% -41.484% 69.66% -52.239%
Efficiency Ratios
Profitability Ratios TTM
Operating Margin
-- -6239.069% -- -9436.077% -- -17730.340% -- -45855.556%
Net Margin
-- -6257.017% -- -9634.498% -- -18193.204% -- -47416.667%
EBITDA Margin
-- -62.2382% -- -93.8061% -- -176.3155% -- -458.2153%
R & D Expense Ratio
-- 4653.980% -- 6831.000% -- 12696.120% -- 33239.580%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 1495.140% -- 2422.440% -- 4675.730% -- 11529.860%
Financial Health Ratios
Long-Term Debt to Equity Ratio
370.82% 15.994% -- 13.799% -- 12.160% -- 9.903%
Total Assets to Common Equity
15.25% 127.246% -- 122.659% -- 119.822% -- 116.301%
Debt to Asset Ratio
214.85% 17.126% -- 14.856% -- 13.334% -- 9.903%
Current Ratio
-34.34% 10.9565 26.73% 13.4565 5.98% 15.2311 513.73% 19.1343
Quick Ratio
-37.94% 10.1772 23.82% 12.8489 5.21% 14.9299 526.97% 18.8474
GrowthRatios
Growth Ratios
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. It offers its product under the OMEGA platform. The company was founded by Noubar B. Afeyan and David Berry on July 13, 2016 and is headquartered in Cambridge, MA.
CEO: Mr. Mahesh Karande
Market: NASDAQ
Listing Date: 07/30/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist